The company lacks commercial revenue and continues to report significant operating losses, with quarterly deficits ranging from $2.5 million to $5.1 million over the last ten quarters.
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 7K | 26K | 0 | 147K | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | -7K | -26K | 0 | -147K | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | 100% | - | - | - | - | - |
| Operating Expenses | 11.1M | 11.97M | 16.59M | 8.17M | 7.55M | 8.01M | 6.22M | 5.68M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 5.31M | 5.19M | 6.09M | 3.39M | 2.42M | 2.14M | 1.17M | 1.24M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - |
| Research & Development | 5.79M | 6.79M | 10.5M | 4.79M | 5.13M | 5.86M | 5.05M | 4.44M |
| R&D % of Revenue | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 17.22K | 0 | 0 |
| Operating Income | -11.1M | -11.97M | -16.59M | -8.32M | -7.55M | -8.01M | -6.22M | -5.68M |
| Operating Margin % | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | 27.81% | -99.36% | -10.19% | 5.79% | -28.77% | -9.65% | - |
| EBITDA | -8.37M | -11.97M | -16.27M | -8.17M | -7.5M | -7.88M | -6.03M | -5.5M |
| EBITDA Margin % | - | - | - | - | - | - | - | - |
| EBITDA Growth % | 44.77% | 26.41% | -99.07% | -8.96% | 4.8% | -30.64% | -9.57% | - |
| D&A (Non-Cash Add-back) | 2.73M | 0 | 0 | 147K | 0 | 0 | 0 | 171.86K |
| EBIT | -11.04M | -11.97M | -16.27M | -10.23M | -7.5M | -7.88M | -6.03M | -5.38M |
| Net Interest Income | 258K | 180K | 314K | 19K | -79.3K | -14.16K | 74.01K | 150.71K |
| Interest Income | 258K | 180K | 314K | 324K | 2.48K | 2.61K | 74.01K | 150.71K |
| Interest Expense | 0 | 0 | 0 | 305K | 81.78K | 16.77K | 0 | 0 |
| Other Income/Expense | 411K | 366K | 317K | -2.22M | -32K | 118.58K | 192.77K | 295.7K |
| Pretax Income | -10.69M | -11.61M | -16.27M | -10.54M | -7.58M | -7.9M | -6.03M | -5.38M |
| Pretax Margin % | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -10.69M | -11.61M | -16.27M | -10.54M | -7.58M | -7.9M | -5.96M | -5.23M |
| Net Margin % | - | - | - | - | - | - | - | - |
| Net Income Growth % | 28.77% | 28.66% | -54.37% | -38.99% | 3.97% | -32.55% | -13.91% | - |
| Net Income (Continuing) | -10.69M | -11.61M | -16.27M | -10.54M | -7.58M | -7.9M | -6.03M | -5.38M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.42 | -8.56 | -29.25 | -34.50 | -55.50 | -58.00 | -44.25 | -39.50 |
| EPS Growth % | 73.45% | 70.73% | 15.22% | 37.84% | 4.31% | -31.07% | -12.03% | - |
| EPS (Basic) | - | -8.56 | -29.25 | -34.50 | -55.50 | -58.00 | -44.25 | -39.50 |
| Diluted Shares Outstanding | 25.34M | 13.56M | 556.28K | 344.65K | 136.4K | 136.4K | 136.38K | 136.12K |
| Basic Shares Outstanding | 25.34M | 13.56M | 556.24K | 306.16K | 136.4K | 136.4K | 136.36K | 136.08K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
Clinical-stage liquidity constraints
As reported in financial statements, Intensity Therapeutics maintains a high-fixed cost structure, with quarterly R&D expenditures fluctuating between $1.2 million and $3.6 million, reflecting the intensive nature of managing multi-arm clinical trials without the offset of any commercial revenue streams to stabilize the bottom line.
The company's cost structure is almost entirely comprised of R&D and SG&A, which underscores its status as a pure-play clinical development entity. Investors should note that the absence of revenue means these costs directly translate into a persistent, non-cyclical cash burn that necessitates ongoing external financing.
Based on the company's reported figures, stock-based compensation has periodically accounted for a significant portion of operating expenses, reaching as high as $844,000 in 2024Q4, which complicates the assessment of true cash-based operating losses versus non-cash accounting charges inherent in the firm's current compensation strategy.
The volatility in stock-based compensation suggests that management's reliance on equity-based incentives may be masking the underlying cash burn rate. Analysts should monitor these non-cash charges closely, as they may artificially inflate the reported operating loss while potentially diluting existing shareholders to preserve limited cash reserves.
According to recent SEC filings, the company's operating income remains consistently negative, with quarterly losses ranging from $2.5 million to $5.1 million, indicating that the firm has yet to achieve the scale required to leverage its fixed R&D infrastructure against any meaningful top-line growth.
The lack of operating leverage is a structural reality for a pre-revenue biotech firm, where expenses are driven by trial enrollment rather than sales volume. Until the company achieves a clinical milestone that triggers partnership payments, the operating margin will remain deeply negative and entirely dependent on capital raises.
With cash and equivalents reported at $11.9 million, the company faces a precarious financial position, as the current burn rate suggests that the firm may exhaust its available liquidity before reaching critical data readouts, potentially forcing dilutive equity financing in an unfavorable capital market environment.
Short-sellers would likely focus on the narrow runway, arguing that the company's reliance on 'just-in-time' financing creates a binary risk where clinical delays could lead to a liquidity crisis. Investors should consider whether the current cash balance is sufficient to sustain operations through the next major value-inflection point.
Quick answers to the most common questions about buying INTS stock.
For fiscal year 2025, Intensity Therapeutics, Inc. (INTS) reported total revenue of $0.0M.
Intensity Therapeutics, Inc. (INTS) reported a net loss of $11.6M for the fiscal year ending 2025.